Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins

References

• Harris A L. Hypoxia: a key regulatory factor in tumor growth. Nat Rev Cancer 2002; 2: 38–47
   PubMed Web of Science ®Google Scholar
• Holbrook J J, Liljas A, Steindel S J, Rossman M G. Lactate dehydrogenase. The Enzymes, Vol. XI, 3rd edn, P D Boyer. Academic Press, NY 1975; 191–292
   Google Scholar
• Semenza G L, Jiang B H, Leung S W, Passantino R, Concordet J P, Maire P, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996; 271: 32529–32537
   PubMed Web of Science ®Google Scholar
• Koukourakis M I, Giatromanolaki A, Sivridis E. Tumour and angiogenesis research group. Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumor Biol 2003; 24: 199–202
   PubMed Web of Science ®Google Scholar
• Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. German high-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma – a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18: 149–157
   PubMed Web of Science ®Google Scholar
• Ha C S, Kong J S, McLaughlin P, Tucker S L, Fayad L E, Hess M A, et al. Stage III follicular lymphoma: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 2003; 57: 748–754
   PubMed Web of Science ®Google Scholar
• Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921–1925
   PubMed Web of Science ®Google Scholar
• López-Guillermo A, Cid J, Salar A, López A, Montalbán C, Castrillo J M, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998; 9: 849–855
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis M I, Pezzella F, Sivridis E, Turley H, Harris A L, et al. Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol, in press
   PubMed Web of Science ®Google Scholar
• Zaman K, Ryu H, Hall D, O'Donovan K, Lin K I, Miller M P, et al. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-induciblefactor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci 1999; 19: 9821–9830
   PubMed Web of Science ®Google Scholar
• Koukourakis M I, Giatromanolaki A, Harris A L, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 2006; 66: 632–637
   PubMed Web of Science ®Google Scholar
• Talks K L, Turley H, Gatter K C, Maxwell P H, Pugh C W, Ratcliffe P J, et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411–421
   PubMed Web of Science ®Google Scholar
• Turley H, Scott P A, Watts V M, Bicknell R, Harris A L, Gatter K C. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 1998; 186: 313–318
   PubMed Web of Science ®Google Scholar
• Stewart M, Turley H, Cook N, Pezzella F, Pillai G, Ogilvie D, et al. The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology 2003; 43: 33–39
   PubMed Web of Science ®Google Scholar
• Parums D V, Cordell J L, Micklem K, Heryet A R, Gatter K C, Mason D Y. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990; 43: 752–757
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Sivridis E, Gatter K C, Turley H, Harris A L, Koukourakis M I. Tumour and Angiogenesis Research Group. Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Gynecol Oncol 2006; 103: 912–918
   PubMed Web of Science ®Google Scholar
• Koukourakis M I, Giatromanolaki A, Sivridis E, Gatter K C, Harris A L. Tumour Angiogenesis Research Group. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway – a report of the Tumour Angiogenesis Research Group. J Clin Oncol 2006; 24: 4301–4308
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis M I, Kakolyris S, Kaklamanis L, Barbatis K, O'Byrne K J, et al. Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancer. Anticancer Res 1998; 18: 71–76
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis M I, Theodossiou D, Barbatis K, O'Byrne K, Harris A L, et al. Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clin Cancer Res 1997; 3: 2485–2492
   PubMed Web of Science ®Google Scholar
• Koiri R K, Trigun S K, Dubey S K, Singh S, Mishra L. Metal Cu(II) and Zn(II) bipyridyls as inhibitors of lactate dehydrogenase. Biometals 2008; 21: 117–119
   PubMed Web of Science ®Google Scholar
• Major P, Trarbach T, Lenz H, Kerr D, Pendergrass K, Douillard J, et al. A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. J Clin Oncol, 2006 (ASCO Annual Meeting Proceedings Part I); 24 (June 20 Supplement):3529
   Google Scholar
• WHO Classification of Tumors. Pathology and genetics. Tumors of Hematopoietic and Lymphoid Tissues. Lyon: IARC, E S Jaffe, N L Harris, H Stein, J W Vardiman, 2001. p 125
   Google Scholar
• Koster A, van Krieken J H, Mackenzie M A, Schraders M, Borm G F, van der Laak J A, et al. Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 2005; 11: 154–161
   PubMed Web of Science ®Google Scholar
• Ganjoo K N, An C S, Robertson M J, Gordon L I, Sen J A, Weisenbach J, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006; 47: 998–1005
   PubMed Web of Science ®Google Scholar
• Tzankov A, Heiss S, Ebner S, Sterlacci W, Schaefer G, Augustin F, et al. Angiogenesis in nodal B cell lymphomas: a high throughput study. J Clin Pathol 2007; 60: 476–482
   PubMed Web of Science ®Google Scholar
• Gratzinger D, Zhao S, Tibshirani R J, Hsi E D, Hans C P, Pohlman B, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 2008; 88: 38–47
   PubMed Web of Science ®Google Scholar
• Jørgensen J M, Sørensen F B, Bendix K, Nielsen J L, Olsen M L, Funder A M, et al. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 2007; 48: 584–595
   PubMed Web of Science ®Google Scholar
• Bairey O, Zimra Y, Kaganovsky E, Shaklai M, Okon E, Rabizadeh E. Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Med Oncol 2000; 17: 314–318
   PubMed Web of Science ®Google Scholar